Skip to content

Post-market Evaluation of Clinical Outcomes in China for the TECNIS Model ZMT

Post-market Evaluation of Clinical Outcomes in China for the TECNIS® Multifocal Toric 1-Piece Intraocular Lens Model Series ZMT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04954898
Enrollment
102
Registered
2021-07-08
Start date
2021-08-11
Completion date
2024-01-10
Last updated
2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

This is a prospective, multicenter, single-arm, open-label clinical study of the commercially available TECNIS Multifocal Toric 1-Piece IOL. The study will enroll up to 120 subjects from up to 8 sites in China. The subjects will be followed for 12-months postoperatively.

Interventions

DEVICEStudy Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT

Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.

Sponsors

Johnson & Johnson Surgical Vision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female at least 22 years of age 2. Have a cataract in one or both eyes, with planned phacoemulsification with intraocular lens implantation 3. Regular corneal astigmatism that is planned for correction with an intraocular lens in the study eye(s) 4. Availability, willingness and sufficient cognitive awareness to understand the purpose of the examination procedures and comply with postoperative visits that are required by the study protocol 5. Voluntary participation indicated by the study informed consent form (ICF) signed by the patient or legal guardian.

Exclusion criteria

1. Concurrent participation or participation in any other clinical study within 30 days prior to the preoperative visit 2. Ocular disease (other than cataract) that may significantly affect postoperative vision, such as visually significant keratopathy, macular lesions, diabetic retinopathy, chronic or severe uveitis, etc. 3. Planned monovision correction (one eye designated for near correction) 4. Severe or unstable systemic disease that may affect the heart, liver, kidney, lung, endocrine (including thyroid insufficiency), blood, or psychoneurological dysfunction 5. Any other systemic or ocular disease that, in the opinion of the investigator, may affect the patient's eligibility for the study. \-

Design outcomes

Primary

MeasureTime frameDescription
The percentage of eyes that are measured at the 1-day postoperative visit to demonstrate ≤10º change from The intended IOL axis at the end of surgery.1 day postoperativeThe axis change is calculated as the absolute difference between intended IOL axis and the axis measured at follow-up visit(s).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026